From None: 2025-01-13 16:00:01

In recent news, iRhythm Technologies has experienced fluctuating price targets, with a high of $120 last month compared to $98.2 the previous quarter. Analysts are optimistic due to a partnership with Verily Life Sciences LLC to develop atrial fibrillation screening products. The growing demand for digital healthcare solutions also supports iRhythm’s growth potential, with a notable price target of $179 from Needham. Investors should stay tuned for upcoming updates from the company.



Read more at None:: iRhythm Technologies, Inc. (NASDAQ:IRTC) – A Leade…